These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 26029997)

  • 21. Oxidation of structural cysteine residues in thioredoxin 1 by aromatic arsenicals enhances cancer cell cytotoxicity caused by the inhibition of thioredoxin reductase 1.
    Zhang X; Lu J; Ren X; Du Y; Zheng Y; Ioannou PV; Holmgren A
    Free Radic Biol Med; 2015 Dec; 89():192-200. PubMed ID: 26169724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
    Cheok CF; Dey A; Lane DP
    Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of auranofin-induced apoptosis in MCF-7 human breast cells by selenocystine, a synergistic inhibitor of thioredoxin reductase.
    Liu C; Liu Z; Li M; Li X; Wong YS; Ngai SM; Zheng W; Zhang Y; Chen T
    PLoS One; 2013; 8(1):e53945. PubMed ID: 23342042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Auranofin, a thioredoxin reductase inhibitor, causes platelet death through calcium overload.
    Harper MT
    Platelets; 2019; 30(1):98-104. PubMed ID: 29194002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic targeting of TrxR1 and ATM/AKT pathway in human colon cancer cells.
    Shen X; Xia Y; Lu H; Zheng P; Wang J; Chen Y; Xu C; Qiu C; Zhang Y; Xiao Z; Zou P; Cui R; Ni D
    Biomed Pharmacother; 2024 May; 174():116507. PubMed ID: 38565059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer.
    Freire Boullosa L; Van Loenhout J; Flieswasser T; De Waele J; Hermans C; Lambrechts H; Cuypers B; Laukens K; Bartholomeus E; Siozopoulou V; De Vos WH; Peeters M; Smits ELJ; Deben C
    Redox Biol; 2021 Jun; 42():101949. PubMed ID: 33812801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of TrxR1 inhibitor and lenvatinib triggers ROS-dependent cell death in human lung cancer cells.
    Zheng P; Xia Y; Shen X; Lu H; Chen Y; Xu C; Qiu C; Zhang Y; Zou P; Cui R; Huang X
    Int J Biol Sci; 2024; 20(1):249-264. PubMed ID: 38164168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Auranofin is a potent suppressor of osteosarcoma metastasis.
    Topkas E; Cai N; Cumming A; Hazar-Rethinam M; Gannon OM; Burgess M; Saunders NA; Endo-Munoz L
    Oncotarget; 2016 Jan; 7(1):831-44. PubMed ID: 26573231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Menin‑MLL inhibitors induce ferroptosis and enhance the anti‑proliferative activity of auranofin in several types of cancer cells.
    Kato I; Kasukabe T; Kumakura S
    Int J Oncol; 2020 Oct; 57(4):1057-1071. PubMed ID: 32945449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ROS-mediated inactivation of the PI3K/AKT pathway is involved in the antigastric cancer effects of thioredoxin reductase-1 inhibitor chaetocin.
    Wen C; Wang H; Wu X; He L; Zhou Q; Wang F; Chen S; Huang L; Chen J; Wang H; Ye W; Li W; Yang X; Liu H; Peng J
    Cell Death Dis; 2019 Oct; 10(11):809. PubMed ID: 31649256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1).
    Omata Y; Folan M; Shaw M; Messer RL; Lockwood PE; Hobbs D; Bouillaguet S; Sano H; Lewis JB; Wataha JC
    Toxicol In Vitro; 2006 Sep; 20(6):882-90. PubMed ID: 16510263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase.
    Malin D; Lee Y; Chepikova O; Strekalova E; Carlson A; Cryns VL
    Breast Cancer Res Treat; 2021 Dec; 190(3):373-387. PubMed ID: 34553295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
    Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
    Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Menadione Potentiates Auranofin-Induced Glioblastoma Cell Death.
    Szeliga M; Rola R
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.
    Verhaegen M; Bauer JA; Martín de la Vega C; Wang G; Wolter KG; Brenner JC; Nikolovska-Coleska Z; Bengtson A; Nair R; Elder JT; Van Brocklin M; Carey TE; Bradford CR; Wang S; Soengas MS
    Cancer Res; 2006 Dec; 66(23):11348-59. PubMed ID: 17145881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Substrate and inhibitor specificities differ between human cytosolic and mitochondrial thioredoxin reductases: Implications for development of specific inhibitors.
    Rackham O; Shearwood AM; Thyer R; McNamara E; Davies SM; Callus BA; Miranda-Vizuete A; Berners-Price SJ; Cheng Q; Arnér ES; Filipovska A
    Free Radic Biol Med; 2011 Mar; 50(6):689-99. PubMed ID: 21172426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase.
    Gandin V; Fernandes AP; Rigobello MP; Dani B; Sorrentino F; Tisato F; Björnstedt M; Bindoli A; Sturaro A; Rella R; Marzano C
    Biochem Pharmacol; 2010 Jan; 79(2):90-101. PubMed ID: 19665452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
    Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.